Intensification of antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 17, Issue 6, 2001, Pages 499-506

  Núñez, Marina ^a   Rodríguez Rosado, Rafael ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CELL ACTIVATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERANCE; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HUMANS;

EID: 0034928504     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220151126544     Document Type: Article

References (86)

1. Antiretroviral therapy in adults. Updated recommendations of the IAS-USA Panel
2. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
3. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
4. Resistance profiles in patients with viral rebound on potent antiretroviral therapy
5. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
6. Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy
7. Adverse drug reactions in patients with HIV infection. A prospective study
8. Insights into the reasons for discontinuation of the first HAART regimen in a cohort of antiretroviral naive patients
9. Strategies for long-term success in the treatment of HIV infection
10. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection
11. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy
12. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
13. The effect of treatment intensification in HIV infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
14. The role of abacavir in antiretroviral therapy-experienced patients: Results from a randomized, double-blind, trial
15. Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients. A double blind, placebo-controlled study
16. Heterogeneity in the response to antiretroviral therapy
17. + lymphocyte counts and the risk of progression to AIDS
18. The relation of virologic and immunologic markers to clinical outcomes after nucleo-side therapy in HIV-infected adults with 200-500 CD4 cells per cubic millimeter
19. Monitoring plasma HIV-1 levels in addition to CD4 lymphocyte count improves assessment of antiretroviral therapeutic response
20. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
21. Use of changes in plasma levels of HIV type 1 RNA to assess the clinical benefit of anti-retroviral therapy
22. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
23. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zi-dovudine for HIV-infected patients. The INCAS trial
24. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
25. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy
26. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy
27. Drug resistance testing: Time to be used in clinical practice?
28. Introduction of HIV drug resistance testing in clinical practice
29. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less
30. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
31. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
32. Factors that predict incomplete virological response to protease inhibitor-based anti-retroviral therapy
33. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
34. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
35. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
36. Viral dynamics in human immunodeficiency virus type 1 infection
37. Decay characteristics of HIV-1 infected compartments during combination therapy
38. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active anti-retroviral therapy
39. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
40. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
41. Time course of cerebrospinal fluid (CSF) responses to antiretroviral therapy: Evidence for variable compartmentalization of infection
42. A stable reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children
43. Latency and reservoirs for HIV-1
44. Strong HIV-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
45. Compartmentalization in HIV infection
46. Significance of P-glyco-protein for the pharmacology and clinical use of HIV protease inhibitors
47. Significance of P-glycopro-tein for the pharmacology and clinical use of HIV protease inhibitors
48. Induction-maintenance (5 → 3 drugs) in HIV-infected patients with high viral load
49. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple drug therapy
50. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients
51. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) Study
52. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
53. Efficiency of drug resistance genotypic tests in specimens with low HIV viral load
54. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the HIV-1 reverse transcriptase
55. Simplified maintenance therapy with abacavir + lamivudine + zidovudine in patients with HAART-induced long-term suppression of HIV-1 RNA: Final results
56. A novel HIV-1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
57. Spanish consensus on drug resistance testing in clinical practice
58. Antiretroviral treatment in 1998
59. Analysis of HIV-1 clinical trials: Statistical magic?
60. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy
61. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
62. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
63. Can early failure with nevirapine be rescued with efavirenz?
64. Can early failure with nevirapine (NVP)-based regimens be rescued replaying NVP by efavirenz?
65. The presence or absence of zidovudine in a nevirapine-contianing antiretroviral regimen determines which of two nevirapine-limiting mutations occur on virologic failure
66. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
67. Novel four-drug salvage treatment regimens after failure of a HIV-1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
68. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome on therapy
69. Immune restoration by combination of a cytostatic drug (hy-droxyurea) and anti-HIV drugs (didanosine and indinavir)
70. Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy
71. Long-term treatment experience of hydroxiurea (HU) in combination with didanosine and stavudine
72. Randomized trial of continued indinavir (IDV)/AZT/3TC vs. switch to IDV/ddI/d4T or IDV/ddI/d4T + hydroxyurea in patients with viral suppression
73. Treatment of primary HIV infection with ddI, d4T, nevirapine, and hydroxyurea: A pilot study
74. What dual protease inhibitor combination for salvage therapies?
75. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
76. Ritonavir intensification in indinavir recipients with detectable HIV RNA levels
77. Multiple-dose pharmacokinetics and tolerability of indinavir and ritonavir combinations in healthy volunteers
78. Phenotypic sensitivity to 1592 (ABC) in the presence of multiple genotypic mutations: Correlation with viral load reponse
79. Mitochondrial toxicity of NRTIs: Lactic acidosis, risk factors and therapeutic options
80. HIV-1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
81. Abacavir in combination with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid is active against multidrug-resistance HIV
82. Interactions of antiretroviral drugs
83. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir
84. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities